Current race in the development of DAAs (direct-acting antivirals) against HCV

Biochemical Pharmacology

Volumn 89, Issue 4, 2014, Pages 441-452

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Direct acting antivirals; Hepatitis C virus (HCV); NS3 4A protease inhibitors; NS5A protein inhibitors; NS5B (non nucleoside type) polymerase inhibitors; NS5B (nucleoside type) polymerase inhibitors

Indexed keywords

ABT 450; ACH 2928; ACH 3102; ALS 2158; ANTIVIRUS AGENT; ASUNAPREVIR; AZD 7295; BOCEPREVIR; DACLATASVIR; DANOPREVIR; DELDEPREVIR; DIRECT ACTING ANTIVIRAL AGENT; FALDAPREVIR; GS 0938; GS 9256; GSK 2336805; LEDIPASVIR; MERICITABINE; MK 5172; MK 8742; OMBITASVIR; PPI 668; SIMEPREVIR; SOFOSBUVIR; SOVAPREVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANIPREVIR; VCH 916; VEDROPREVIR; VX 135;

HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PRIORITY JOURNAL; REVIEW; SUSTAINED VIRAL RESPONSE; TREATMENT DURATION; VIRAL PHENOMENA AND FUNCTIONS; VIRUS REPLICATION;

ASUNAPREVIR (PUBCHEM CID: 16076883); BOCEPREVIR (PUBCHEM CID: 10324367); DACLATASVIR (PUBCHEM CID: 25154714); DANOPREVIR (PUBCHEM CID: 71301228); DELEOBUVIR (PUBCHEM CID: 56948249); DIRECT-ACTING ANTIVIRALS; FALDAPREVIR (PUBCHEM CID: 71300931); HEPATITIS C VIRUS (HCV); LEDIPASVIR (PUBCHEM CID: 67505836); MERICITABINE (PUBCHEM CID: 16122663); NARLAPREVIR (PUBCHEM CID: 11857239); NECEPREVIR (PUBCHEM CID: 71301413); NS3/4A PROTEASE INHIBITORS; NS5A PROTEIN INHIBITORS; NS5B (NON-NUCLEOSIDE-TYPE) POLYMERASE INHIBITORS; NS5B (NUCLEOSIDE-TYPE) POLYMERASE INHIBITORS; SETROBUVIR (PUBCHEM CID: 45136829); SIMEPREVIR (PUBCHEM CID: 24873435); SOFOSBUVIR (PUBCHEM CID: 45375808); SOVAPREVIR (PUBCHEM CID: 53362096); TEGOBUVIR (PUBCHEM CID: 23649154); TELAPREVIR (PUBCHEM CID: 3010818); VANIPREVIR (PUBCHEM CID: 24765256); VEDROPREVIR (PUBCHEM CID: 25167947);

ANIMALS; ANTIVIRAL AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HEPACIVIRUS; HEPATITIS C; HUMANS; MOLECULAR TARGETED THERAPY; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84901627635     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.04.005     Document Type: Note

References (109)

1. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965 (Pubitemid 32913521)
2. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Gonçales Jr. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
3. J.G. McHutchison, E.J. Lawitz, M.L. Shiffman, A.J. Muir, G.W. Galler, and J. McCone et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593
4. J.G. McHutchison, G.T. Everson, S.C. Gordon, I.M. Jacobson, M. Sulkowski, and R. Kauffman et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 1838
5. J.G. McHutchison, M.P. Manns, A.J. Muir, N.A. Terrault, I.M. Jacobson, and N.H. Afdhal et al. Telaprevir for previously treated chronic HCV infection N Engl J Med 362 2010 1292 1303
6. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
7. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, and S. Roberts et al. Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
8. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
9. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem et al. Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
10. E. De Clercq The race for interferon-free HCV therapies: a snapshot by the spring of 2012 Rev Med Virol 22 2012 392 411
11. E.J. Gane, C.A. Stedman, R.H. Hyland, X. Ding, E. Svarovskaia, and W.T. Symonds et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C N Engl J Med 368 2013 34 44
12. I.M. Jacobson, S.C. Gordon, K.V. Kowdley, E.M. Yoshida, M. Rodriguez-Torres, and M.S. Sulkowski et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N Engl J Med 368 2013 1867 1877
13. E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-Torres, T. Hassanein, and S.C. Gordon et al. Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
14. K.L. Berger, L. Lagacé, I. Triki, M. Cartier, M. Marquis, and C. Lawetz et al. Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study Antimicrob Agents Chemother 57 2013 4928 4936
15. S. Zeuzem, T. Asselah, P. Angus, J.P. Zarski, D. Larrey, and B. Müllhaupt et al. Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results Antivir Ther 18 2013 1015 1019
16. F. McPhee, A.K. Sheaffer, J. Friborg, D. Hernandez, P. Falk, and G. Zhai et al. Preclinical profile and characterization of the hepatitis C Virus NS3 protease inhibitor asunaprevir (BMS-650032) Antimicrob Agents Chemother 56 2012 5387 5396
17. J.P. Bronowicki, S. Pol, P.J. Thuluvath, D. Larrey, C.T. Martorell, and V.K. Rustgi et al. Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C Antivir Ther 18 2013 885 893
18. X.C. Sheng, A. Casarez, R. Cai, M.O. Clarke, X. Chen, and A. Cho et al. Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity Bioorg Med Chem Lett 22 2012 1394 1396
19. S. Zeuzem, P. Buggisch, K. Agarwal, P. Marcellin, D. Sereni, and H. Klinker et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C Hepatology 55 2012 749 758
20. H. Yang, M. Robinson, A.C. Corsa, B. Peng, G. Cheng, and Y. Tian et al. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451 Antimicrob Agents Chemother 58 2014 647 653
21. Y. Jiang, S.W. Andrews, K.R. Condroski, B. Buckman, V. Serebryany, and S. Wenglowsky et al. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C Virus (HCV) NS3/4A protease J Med Chem 57 2014 1753 1769
22. V. Summa, S.W. Ludmerer, J.A. McCauley, C. Fandozzi, C. Burlein, and G. Claudio et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants Antimicrob Agents Chemother 56 2012 4161 4167
23. K.P. Romano, A. Ali, C. Aydin, D. Soumana, A. Ozen, and L.M. Deveau et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors PLoS Pathog 8 2012 e1002832
24. J. Kong, C.Y. Chen, J. Balsells-Padros, Y. Cao, R.F. Dunn, and S.J. Dolman et al. Synthesis of the HCV protease inhibitor vaniprevir (MK-7009) using ring-closing metathesis strategy J Org Chem 77 2012 3820 3828
25. R.J. Barnard, C.M. McHale, W. Newhard, C.A. Cheney, D.J. Graham, and A.L. Himmelberger et al. Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis Virology 443 2013 278 284
26. E. Lawitz, M. Sulkowski, I. Jacobson, W.K. Kraft, B. Maliakkal, and M. Al-Ibrahim et al. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics Antiviral Res 99 2013 214 220
27. M.P. Manns, E. Gane, M. Rodriguez-Torres, A. Stoehr, C.T. Yeh, and P. Marcellin et al. Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study Hepatology 56 2012 884 893
28. M. Rodriguez-Torres, A. Stoehr, E. Gane, L. Serfaty, E. Lawitz, and M. Bourque et al. Sustained viral response and safety of MK-7009 in cirrhotic treatment-experienced patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment Abstracts of the 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013) Amsterdam, The Netherlands, 24-28 April 2013 2013 S47 J Hepatol, 58, Suppl. 1
29. E. Lawitz, M. Rodriguez-Torres, A. Stoehr, E.J. Gane, L. Serfaty, and S. Bhanja et al. A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment J Hepatol 59 2013 11 17
30. A. Agarwal, B. Zhang, E. Olek, H. Robison, L. Robarge, and M. Deshpande Rapid and sharp decline in HCV upon monotherapy with NS3 protease inhibitor, ACH-1625 Antivir Ther 17 2012 1533 1539
31. J. Fabrycki, Y. Zhao, D. Patel, G. Yang, S. Podos, and W. Yang et al. Findings from clinical virology studies on sovaprevir, a phase 2 HCV NS3 protease inhibitor, indicate a high pharmacological barrier to viral resistance Abstracts of the 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013) Amsterdam, The Netherlands, 24-28 April 2013 2013 S488 J Hepatol. 58, Suppl. 1
32. E. Lawitz, J. Hill, B. Vince, A. Murillo, D. Gruener, and T. Marbury et al. ACH-2684 demonstrates potent viral suppression in genotype 1 hepatitis C patients with and without cirrhosis: safety, pharmacokinetic, and viral kinetic analysis Abstracts of the 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013) Amsterdam, The Netherlands, 24-28 April 2013 2013 S347 J Hepatol. 58, Suppl. 1
33. D.M. Hotho, J. de Bruijne, M. Spaan, M.A. Treitel, A. Boonstra, and R.J. de Knegt et al. Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up J Viral Hepat 20 2013 e78 e81
34. R. Flisiak, J. Jaroszewicz, and A. Parfieniuk-Kowerda Emerging treatments for hepatitis C Expert Opin Emerg Drugs 18 2013 461 475
35. D.M. You, and P.J. Pockros Simeprevir for the treatment of chronic hepatitis C Expert Opin Pharmacother 14 2013 2581 2589
36. M.W. Fried, M. Buti, G.J. Dore, R. Flisiak, P. Ferenci, and I. Jacobson et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study Hepatology 58 2013 1918 1929
37. N. Hayashi, C. Seto, M. Kato, Y. Komada, and S. Goto Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study J Gastroenterol 49 2014 138 147
38. J.J. Kiser, J.R. Burton Jr., and G.T. Everson Drug-drug interactions during antiviral therapy for chronic hepatitis C Nat Rev Gastroenterol Hepatol 10 2013 596 606
39. B. Moreau, J.A. O'Meara, J. Bordeleau, M. Garneau, C. Godbout, and V. Gorys et al. Discovery of hepatitis C virus NS3-4A protease inhibitors with improved barrier to resistance and favorable liver distribution J Med Chem 57 2014 1770 1776
40. J.F. Miller, P.Y. Chong, J.B. Shotwell, J.G. Catalano, V.W. Tai, and J. Fang et al. Hepatitis C replication inhibitors that target the viral NS4B protein J Med Chem 57 2014 2107 2120
41. N. Zhang, X. Zhang, J. Zhu, A. Turpoff, G. Chen, and C. Morrill et al. Structure-activity relationship (SAR) optimization of 6-(Indol-2-yl)pyridine-3- sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B J Med Chem 57 2014 2121 2135
42. Lambert SM, Langley DR, Garnett JA, Angell R, Hedgethorne K, Meanwell NA, et al. The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors. Protein Sci 2014;in press.
43. M. Gao Antiviral activity and resistance of HCV NS5A replication complex inhibitors Curr Opin Virol 3 2013 514 520
44. D.A. Degoey, J.T. Randolph, D. Liu, J. Pratt, C. Hutchins, and P. Donner et al. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A J Med Chem 57 2014 2047 2057
45. M. Bifano, C. Hwang, B. Oosterhuis, J. Hartstra, D. Grasela, and R. Tiessen et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir Antivir Ther 18 2013 931 940
46. D.R. O'Boyle Ii, J.H. Sun, P.T. Nower, J.A. Lemm, R.A. Fridell, and C. Wang et al. Characterizations of HCV NS5A replication complex inhibitors Virology 444 2013 343 354
47. J.O. Link, J.G. Taylor, L. Xu, M. Mitchell, H. Guo, and H. Liu et al. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection J Med Chem 57 2014 2033 2046
48. K.A. Wong, A. Worth, R. Martin, E. Svarovskaia, D.M. Brainard, and E. Lawitz et al. Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885 Antimicrob Agents Chemother 57 2013 6333 6340
49. E.J. Lawitz, D. Gruener, J.M. Hill, T. Marbury, L. Moorehead, and A. Mathias et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C J Hepatol 57 2012 24 31
50. B. Vince, E. Lawitz, S. Searle, T. Marbury, H. Robison, and L. Robarge et al. Novel NS5A inhibitor ACH-2928 phase 1 results in healthy volunteers and HCV GT-1 patients Abstracts of the 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012) Barcelona, Spain, 18-22 April 2012 2012 S480 S481 J Hepatol. 56, Suppl. 1
51. www.achillion.com. ACH-3102 at-a-glance. Press release; 2012.
52. J. Lalezari, G. Farrell, P. Shah, E. Lawitz, C. Schwabe, and D. Walsh et al. PPI-668, a potent new pan-genotypic HCV NS5A inhibitor: phase 1 efficacy and safety Abstracts of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA, 9-12 November 2012 2012 065A Hepatology. 56
53. E. Gane, G.R. Foster, J. Cianciara, C. Stedman, S. Ryder, and M. Buti et al. Antiviral activity, pharmacokinetics, and tolerability of AZD7295, a novel NS5A inhibitor, in a placebo-controlled multiple ascending dose study in HCV genotype 1 and 3 patients Abstracts of the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) Vienna, Austria, 14-18 April 2010 2010 S464 J Hepatol. 52
54. C.A. Coburn, P.T. Meinke, W. Chang, C.M. Fandozzi, D.J. Graham, and B. Hu et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity ChemMedChem 8 2013 1930 1940
55. R. Liu, R. Kong, P. Mann, P. Ingravallo, Y. Zhai, and E. Xia et al. In vitro resistance analysis of Merck's HCV NS5a inhibitor MK-8742 demonstrates increased potency against clinical resistance variants and improved resistance profile Abstracts of the 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012) Barcelona, Spain, 18-22 April 2012 2012 S334 S335 J Hepatol. 56, Suppl. 2
56. D.A. Wilfret, J. Walker, K.K. Adkison, L.A. Jones, Y. Lou, and J. Gan et al. Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1 Antimicrob Agents Chemother 57 2013 5037 5044
57. D.R. St Laurent, M.H. Serrano-Wu, M. Belema, M. Ding, H. Fang, and M. Gao et al. HCV NS5A replication complex inhibitors. Part 4. (1) Optimization for genotype 1a replicon inhibitory activity J Med Chem 57 2014 1976 1994
58. M. Belema, V.N. Nguyen, and J.L. Romine St Laurent DR, Lopez OD, Goodrich JT, et al. Hepatitis C virus NS5A replication complex inhibitors. Part 6: discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons J Med Chem 57 2014 1995 2012
59. I. Gentile, F. Borgia, A.R. Buonomo, G. Castaldo, and G. Borgia A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir Curr Med Chem 20 2013 3733 3742
60. T. Asselah Sofosbuvir-based interferon-free therapy for patients with HCV infection J Hepatol 59 2013 1342 1345
61. A. Osinusi, E.G. Meissner, Y.J. Lee, D. Bon, L. Heytens, and A. Nelson et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial JAMA 310 2013 804 811
62. A.M. Lam, C. Espiritu, S. Bansal, H.M. Miclochick Steuer, V. Zennou, and M.J. Otto et al. Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA J Virol 85 2011 12334 12342
63. A.M. Lam, C. Espiritu, E. Murakami, V. Zennou, S. Bansal, and H.M. Micolochick Steuer et al. Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2′-deoxy-2′- α-fluoro-2′-β-C-methylguanosine Antimicrob Agents Chemother 55 2011 2566 2575
64. P.G. Reddy, D. Bao, W. Chang, B.K. Chun, J. Du, and D. Nagarathnam et al. 2′-Deoxy-2′-α-fluoro-2′-β-C-methyl 3′,5′-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: discovery of PSI-352938 Bioorg Med Chem Lett 20 2010 7376 7380
65. E.J. Lawitz, M. Rodriguez-Torres, J. Denning, A. Mathias, H. Mo, and B. Gao et al. All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear) J Viral Hepat 20 2013 699 707
66. J. Guedj, H. Dahari, E. Shudo, P. Smith, and A.S. Perelson Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128) Hepatology 55 2012 1030 1037
67. J.M. Pawlotsky, I. Najera, and I. Jacobson Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase Antivir Ther 17 2012 411 423
68. P.J. Pockros, D. Jensen, N. Tsai, R. Taylor, A. Ramji, and C. Cooper et al. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients Hepatology 58 2013 514 523
69. H. Wedemeyer, D. Jensen, R. Herring Jr., P. Ferenci, M.M. Ma, and S. Zeuzem et al. PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients Hepatology 58 2013 524 537
70. D.M. Torres, and S.A. Harrison Small steps toward a better treatment for chronic hepatitis C infection: mericitabine, pegylated interferon, and ribavirin in the PROPEL and JUMP-C trials Hepatology 58 2013 488 490
71. X.J. Zhou, K. Pietropaolo, J. Chen, S. Khan, J. Sullivan-Bólyai, and D. Mayers Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects Antimicrob Agents Chemother 55 2011 76 81
72. P. Marcellin, S. Popa, A. Streinu-Cercel, N. Boyer, D. Dospinoiu, and A. Patat et al. ALS-2200, a novel once-daily nucleotide HCV polymerase inhibitor, demonstrated potent antiviral activity in treatment-naïve patients with compensated cirrhosis or genotype 2-4 chronic hepatitis C Abstracts of the International Liver Congress™ 2013-48th Annual Meeting of the European Association for the Study of the Liver Amsterdam, The Netherlands, 24 April 2013-28 April 2013 2013 S355 J Hepatol. 58, Suppl. 1
73. A. Cho, L. Zhang, J. Xu, R. Lee, T. Butler, and S. Metobo et al. Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients J Med Chem 57 2014 1812 1825
74. J. Du, B.K. Chun, R.T. Mosley, S. Bansal, H. Bao, and C. Espiritu et al. Use of 2′-spirocyclic ethers in HCV nucleoside design J Med Chem 57 2014 1826 1835
75. T.H. Jonckers, K. Vandyck, L. Vandekerckhove, L. Hu, A. Tahri, and S. Van Hoof et al. Nucleotide prodrugs of 2′-deoxy-2′-spirooxetane ribonucleosides as novel inhibitors of the HCV NS5B polymerase J Med Chem 57 2014 1836 1844
76. G. Yi, J. Deval, B. Fan, H. Cai, C. Soulard, and C.T. Ranjith-Kumar et al. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir Antimicrob Agents Chemother 56 2012 830 837
77. J. Winquist, E. Abdurakhmanov, V. Baraznenok, I. Henderson, L. Vrang, and U.H. Danielson Resolution of the interaction mechanisms and characteristics of non-nucleoside inhibitors of hepatitis C virus polymerase Antiviral Res 97 2013 356 368
78. D. Larrey, A.W. Lohse, C. Trepo, J.P. Bronowicki, K. Arastéh, and M. Bourlière et al. Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C Antimicrob Agents Chemother 57 2013 4727 4735
79. D. Larrey, A.W. Lohse, V. de Ledinghen, C. Trepo, T. Gerlach, and J.P. Zarski et al. Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin J Hepatol 57 2012 39 46
80. S. Zeuzem, V. Soriano, T. Asselah, J.P. Bronowicki, A.W. Lohse, and B. Müllhaupt et al. Faldaprevir and deleobuvir for HCV genotype 1 infection N Engl J Med 369 2013 630 639
81. I.H. Shih, I. Vliegen, B. Peng, H. Yang, C. Hebner, and J. Paeshuyse et al. Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase Antimicrob Agents Chemother 55 2011 4196 4203
82. K.A. Wong, S. Xu, R. Martin, M.D. Miller, and H. Mo Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a Virology 429 2012 57 62
83. C.M. Hebner, B. Han, K.M. Brendza, M. Nash, M. Sulfab, and Y. Tian et al. The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function PLoS One 7 2012 e39163
84. C. Cooper, E.J. Lawitz, P. Ghali, M. Rodriguez-Torres, F.H. Anderson, and S.S. Lee et al. Evaluation of VCH-759 monotherapy in hepatitis C infection J Hepatol 51 2009 39 46
85. R.G. Gentles, M. Ding, J.A. Bender, C.P. Bergstrom, K. Grant-Young, and P. Hewawasam et al. Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase J Med Chem 57 2014 1855 1879
86. B. Devogelaere, J.M. Berke, L. Vijgen, P. Dehertogh, E. Fransen, and E. Cleiren et al. TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage Antimicrob Agents Chemother 56 2012 4676 4684
87. S. Vendeville, T.I. Lin, L. Hu, A. Tahri, D. McGowan, and M.D. Cummings et al. Finger loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055 Bioorg Med Chem Lett 22 2012 4437 4443
88. M.D. Cummings, T.I. Lin, L. Hu, A. Tahri, D. McGowan, and K. Amssoms et al. Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase J Med Chem 57 2014 1880 1892
89. S. Ramirez, Y.P. Li, S.B. Jensen, J. Pedersen, J.M. Gottwein, and J. Bukh Highly efficient infectious cell culture of three HCV genotype 2b strains and sensitivity to lead protease, NS5A, and polymerase inhibitors Hepatology 59 2014 395 407
90. F.X. Talamas, S.C. Abbot, S. Anand, K.A. Brameld, D.S. Carter, and J. Chen et al. Discovery of N-[4-[6-tert-butyl-5-methoxy-8-(6-methoxy-2-oxo-1H- pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a potent inhibitor of the hepatitis C virus NS5B polymerase J Med Chem 57 2014 1914 1931
91. O. Hucke, R. Coulombe, P. Bonneau, M. Bertrand-Laperle, C. Brochu, and J. Gillard et al. Molecular dynamics simulations and structure-based rational design lead to allosteric HCV NS5B polymerase thumb pocket 2 inhibitor with picomolar cellular replicon potency J Med Chem 57 2014 1932 1943
92. S.E. Lazerwith, W. Lew, J. Zhang, P. Morganelli, Q. Liu, and E. Canales et al. Discovery of GS-9669, a thumb site II non-nucleoside inhibitor of NS5B for the treatment of genotype 1 chronic hepatitis C infection J Med Chem 57 2014 1893 1901
93. P.A. Gallay, and K. Lin Profile of alisporivir and its potential in the treatment of hepatitis C Drug Des Devel Ther 7 2013 105 115
94. J. Guedj, J. Yu, M. Levi, B. Li, S. Kern, and N.V. Naoumov et al. Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in HCV genotype 2/3 patients Hepatology 59 2014 1706 1714
95. F. Poordad, E. Lawitz, K.V. Kowdley, D.E. Cohen, T. Podsadecki, and S. Siggelkow et al. Exploratory study of oral combination antiviral therapy for hepatitis C N Engl J Med 368 2013 45 53
96. T. Asselah ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: a race for an interferon-free regimen to cure HCV infection J Hepatol 59 2013 885 888
97. E. Lawitz, F. Poordad, K.V. Kowdley, D.E. Cohen, T. Podsadecki, and S. Siggelkow et al. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1 J Hepatol 59 2013 18 23
98. F. Poordad, E. Lawitz, K.V. Kowdley, D.E. Cohen, W. Xie, and T. Pilot-Matias et al. Interferon-free regimens of ABT-450/r, ABT-267, ABT-333+-ribavirin achieve high SVR12 and SVR24 rates in patients with chronic HCV genotype 1b Abstracts of the 23rd Conference of the Asian Pacific Association for the Study of the Liver Singapore, 6-10 June 2013 2013
99. S. Zeuzem, T. Asselah, P. Angus, J.P. Zarski, D. Larrey, and B. Müllhaupt et al. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection Gastroenterology 141 2011 2047 2055
100. http://www.natap.org/2013/HCV/031513-01.htm.
101. http://investors.vrtx.com/releasedetail.cfm?releaseID=717777.
102. D.B. Olsen, M.E. Davies, L. Handt, K. Koeplinger, N.R. Zhang, and S.W. Ludmerer et al. Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents Antimicrob Agents Chemother 55 2011 937 939
103. A.S. Lok, D.F. Gardiner, C. Hézode, E.J. Lawitz, M. Bourlière, and G.T. Everson et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders J Hepatol 60 2014 490 499
104. F. McPhee, D. Hernandez, F. Yu, J. Ueland, A. Monikowski, and A. Carifa et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir Hepatology 58 2013 902 911
105. S. Le Pogam, J.M. Yan, M. Chhabra, M. Ilnicka, H. Kang, and A. Kosaka et al. Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir Antimicrob Agents Chemother 56 2012 5494 5502
106. R.J. Fontana, E.A. Hughes, M. Bifano, H. Appelman, D. Dimitrova, and R. Hindes et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C Am J Transplant 13 2013 1601 1605
107. M.S. Sulkowski, D.F. Gardiner, M. Rodriguez-Torres, K.R. Reddy, T. Hassanein, and I. Jacobson et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med 370 2014 211 221
108. E. Gane, R. Hyland, X. Ding, P. Pang, J. McHutchison, and W. Symonds et al. ELECTRON: 100% suppression of viral load through 4 weeks' post-treatment for sofosbuvir + ledipasvir (GS-5885) + ribavirin for 12 weeks in treatment-naive and experienced hepatitis C virus GT1 patients 20th Conference on Retroviruses and Opportunistic Infections. Abstract 41LB Atlanta, 3-6 March 2013 2013
109. E. Lawitz, F.F. Poordad, P.S. Pang, R.H. Hyland, X. Ding, and H. Mo et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial Lancet 383 2014 515 523